Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in Childhood ASD with Gastrointestinal Symptoms
NCT04142255Phase 1Terminated
- Sponsor
- Xinhua Hospital
- Start
- Nov 2019
- Primary completion
- Jun 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fecal microbiome transplant in Autism Spectrum Disorder (ASD), sponsored by Xinhua Hospital. Primary endpoints: Gastrointestinal Symptom Rating Scale at 12 weeks and Childhood Autism Rating Scale at 12 weeks. Started Nov 2019; status: terminated.
02
Drugs
fecal microbiome transplant
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04142255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04142255.